Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (<i>nab</i>)-paclitaxel for newly diagnosed breast cancer (BC).

Khasraw, Mustafa; Mukaro, Violet; West, Linda; Brandt, Conrad; Woollett, Anne; Edwards, Michelle L.; Spokes, Robert; Mitchell, Gregory; Prince, Kimberley; Hayes, Theresa; Collins, Ian M.; Guminski, Alexander; Baron‐Hay, Sally; Olesen, Inger; Bryan, Jacinta; Bowles, Susan K.; Wong, Stephen H.; Ashley, David M.; Patil, Sujata

doi:10.1200/jco.2015.33.15_suppl.e12025

JCO

2015

DOI: 10.1200/jco.2015.33.15_suppl.e12025

|View full text |Cite

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).

Mustafa Khasraw¹,

Violet Mukaro

Linda West

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings

Brufsky

2017

Exp Hematol Oncol

View full text Add to dashboard Cite

PurposeThe purpose of this systematic review is to discuss recent studies and ongoing trials of nab-paclitaxel in breast cancer and to examine the potential role of nab-paclitaxel as a backbone for immuno-oncology therapies.MethodsPubMed and selected congress proceedings were searched for studies of nab-paclitaxel in breast cancer published between 2013 and 2015. All phase II and III clinical trials, retrospective analyses, and institutional studies were included. Active, ongoing, phase II or III trials on nab-paclitaxel that were listed on ClinicalTrials.gov were also included.ResultsSixty-three studies, including 23 in early-stage and 30 in metastatic breast cancer (some studies not classifiable by setting), were included in this analysis. Trials of neoadjuvant nab-paclitaxel–containing regimens have reported pathological complete response rates ranging from 5.7 to 53%. Median overall survival in metastatic breast cancer studies ranged from 10.8 to 23.5 months, depending on dose and regimen. Adverse event profiles of nab-paclitaxel were generally similar to those reported from previous studies. Several ongoing trials are evaluating nab-paclitaxel in the early-stage and metastatic settings, including in combination with immuno-oncology agents.Conclusions nab-Paclitaxel continues to demonstrate promising efficacy in breast cancer. Recent studies demonstrate high pathological complete response rates in early-stage breast cancer, particularly in triple-negative breast cancer, an area of high unmet need, and encouraging overall survival in metastatic breast cancer across doses and schedules. Ongoing trials will provide further insights into the role of nab-paclitaxel in breast cancer including use as a potential backbone chemotherapy agent for immuno-oncology therapies such as checkpoint inhibitors.

show abstract

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings

Brufsky

2017

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).

Cited by 1 publication

References 0 publications

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings

nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings

Contact Info

Product

Resources

About